Challenges and Future Perspectives in Treatment for Lung Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 77
Special Issue Editors
Interests: EGFR; lung cancer; tyrosine kinase inhibitors; monoclonal antibodies; drug resistance
Interests: cancer biology; stat3; signal transduction; chemoresistance; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Lung cancer, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), is the second most common cancer and the leading cause of cancer-related deaths worldwide. The availability of diverse intervention options (surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy) has improved the survival of patients in recent decades. However, additional insights must be gained in order to improve the outcome of this disease.
For this reason, this Special Issue aims to highlight the most recent scientific advances directed at improving the treatment strategies available for both SCLC and NSCLC.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Diagnostic, prognostic and predictive biomarkers in lung cancer;
- Molecular mutations in lung cancer such as the epidermal growth factor receptor (EGFR) gene, ALK rearrangements and KRAS mutations;
- Epidermal growth factor receptor (EFGR)-targeted therapies and drug resistance;
- New therapeutic approaches and drug delivery in lung cancer, such as the role of mutation analysis and next-generation sequencing (NGS) in lung cancer diagnosis and treatment.
Research advances in chemotherapy, targeted therapy and immunotherapy are also welcomed.
We look forward to receiving your contributions.
Dr. Ilaria Marrocco
Dr. Donatella Romaniello
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- non-small cell lung cancer
- small cell lung cancer
- chemotherapy
- targeted therapy
- immunotherapy
- drug resistance
- drug delivery
